(HS Gorman 096247 2022) MDMA-Assisted Therapy in the Treatment of Posttraumatic Stress Disorder
Tracking # 20-941002
Course overview
In the first ever phase 3 trial of MDMA for Posttraumatic Stress Disorder (PTSD), it was reported that 67% of the group who received MDMA, compared to 32% of the group who received placebo, no longer qualified for a PTSD diagnosis after three MDMA treatment sessions. Now, a second Phase 3 clinical trial is nearing completion with a possibility of MDMA becoming an available treatment in the near future. The aim of this recording is to prepare clinicians with an understanding of MDMA-assisted psychotherapy for PTSD in light of this eventuality.
Subject areas
This course counts toward the state boards and subject areas below.
Florida Board of Clinical Social Work, Marriage and Family Therapy and Mental Health Counseling
Certified Master Social Worker
Licensed Clinical Social Worker
Licensed Marriage and Family Therapist
Licensed Mental Health Counselor
Florida Board of Nursing
Advanced Practice Registered Nurse
Licensed Practical Nurse
Registered Nurse
Florida Board of Psychology
Limited License Psychologist
Psychologist
Disclosure statements
Speaker Disclosures:
Financial: Dr. Ingmar Gorman is the co-founder of Fluence and the co-principal investigator and study therapist, MAPS-Sponsored Phase 2/3 MDMA-Assisted Psychotherapy Clinical Trials. He receives royalties as a published author. Dr. Gorman receives a speaking honorarium from Psychotherapy Networker and PESI, Inc. He has no relevant financial relationships with ineligible organizations.
Non-financial: Dr. Ingmar Gorman has no relevant non-financial relationships.